All In Biotech

Drug Trial Radar · NCT06946927

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

A Phase Ib, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of JMKX001899 in Combination With Other Therapies in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation.

Last checked: Nov 20, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Jun 6, 2025

Primary completion

Feb 2026

Study completion Dec 2027

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
First posted
Apr 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of JMKX001899 in combination with IN10018 or in combination with chemotherapy or in combination with IN10018 and chemotherapy in subjects with locally advanced or metastatic NSCLC with KRAS G12C mutation.

Conditions

  • NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

  • JMKX001899Drug

    JMKX001899 tablet administered orally daily.

  • IN10018Drug

    IN10018 tablet administered orally daily.

  • Chemotherapy: PemetrexedDrug

    IV infusion once every 3 weeks

  • CarboplatinDrug

    IV infusion once every 3 weeks, 4 Cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase II dose (RP2D)Time frame: approximately 1 year
  2. adverse eventsTime frame: Through study completion, approximately 2.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.